Company Interview / Artrya's FDA win: A heartbeat away from US market domination

Key points:

Artrya achieves US FDA clearance for commercial sale of coronary anatomy softwareSalix platform uses AI to rapidly diagnose heart disease using CT scansUS market expansion aided by strategic partners and a $15M placement

Artrya CEO Matthew Regan announces the company's milestone achievement of securing US FDA clearance for its coronary anatomy commercial sale, opening access to a vast market. The imaging software, Salix, helps diagnose heart disease using AI technology and provides quick results within ten minutes, setting a foundation for future FDA clearances for challenging diagnostic areas.

Matthew discusses the commercialization strategy, mentioning three strategic US partners, including Tanner Co and Northeast Georgia, conducting 15,000 scans annually. The expansion in the US market offers lucrative opportunities, supported by advantageous CPT rebate codes linked to different products, including coronary anatomy and plaque diagnostics.

A recent $15 million placement supports Artrya's ongoing developments and regulatory approvals. Matthew shares that the company is financially stable with plans to target key US clients and achieve positive cash flow by FY 26. Artrya is poised for significant growth within the lucrative US healthcare market.